Revenue Insights: Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals, Inc. Performance Compared

Comparative Revenue Growth of Takeda and Arrowhead Pharmaceuticals

__timestampArrowhead Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141750001777824000000
Thursday, January 1, 20153820001807378000000
Friday, January 1, 20161583331732051000000
Sunday, January 1, 2017314077091770531000000
Monday, January 1, 2018161423212097224000000
Tuesday, January 1, 20191687955773291188000000
Wednesday, January 1, 2020879920663197812000000
Friday, January 1, 20211382870003569006000000
Saturday, January 1, 20222432310004027478000000
Sunday, January 1, 20232407350004263762000000
Monday, January 1, 202435510004263762000000
Loading chart...

In pursuit of knowledge

Revenue Insights: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals, Inc. stand as intriguing case studies of revenue trajectories over the past decade. From 2014 to 2023, Takeda's revenue has shown a robust growth, peaking at approximately $4.26 trillion in 2023, marking a 140% increase from its 2014 figures. This growth underscores Takeda's strategic expansions and acquisitions, solidifying its position as a global leader.

Conversely, Arrowhead Pharmaceuticals, Inc. has experienced a more volatile revenue journey. Starting with modest figures in 2014, Arrowhead's revenue surged by over 1,300% by 2022, reaching a peak of $243 million. However, 2023 saw a slight dip, indicating potential market challenges or strategic pivots.

This comparative analysis highlights the diverse strategies and market dynamics influencing these pharmaceutical powerhouses, offering valuable insights for investors and industry enthusiasts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025